Towards an updated view on the clinical management of pancreatic adenocarcinoma: Current and future perspectives (Review)
- Authors:
- Leonel Pekarek
- Oscar Fraile‑Μartinez
- Cielo Garcia‑Montero
- Miguel A. Alvarez‑Mon
- Julio Acero
- Lidia Ruiz‑Llorente
- Natalio García‑Honduvilla
- Agustin Albillos
- Julia Buján
- Melchor Alvarez‑Mon
- Luis G. Guijarro
- Miguel A. Ortega
-
Affiliations: Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, Alcala de Henares, 28871 Madrid, Spain, Ramón y Cajal Institute of Sanitary Research, 28034 Madrid, Spain - Published online on: September 27, 2021 https://doi.org/10.3892/ol.2021.13070
- Article Number: 809
-
Copyright: © Pekarek et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
|
Ilic M and Ilic I: Epidemiology of pancreatic cancer. World J Gastroenterol. 28:9694–9705. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74:2913–2921. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Guren MG: The global challenge of colorectal cancer. Lancet Gastroenterol Hepatol. 4:894–895. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Li D: Diabetes and pancreatic cancer. Mol Carcinog. 51:64–74. 2011. View Article : Google Scholar | |
|
Yadav D and Lowenfels AB: The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 144:1252–1261. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ansari D, Tingstedt B, Andersson B, Holmquist F, Sturesson C, Williamsson C, Sasor A, Borg D, Bauden M and Andersson R: Pancreatic cancer: Yesterday, today and tomorrow. Future Oncol. 12:1929–1246. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Maisonneuve P: Epidemiology and burden of pancreatic cancer. Presse Med. 48:e113–e123. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Mizrahi JD, Surana R, Valle JW and Shroff RT: Pancreatic cancer. Lancet. 395:2008–2020. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG and McCain RS: Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 24:4846–4861. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Poruk KE, Firpo MA and Mulvihill SJ: Screening for pancreatic cancer. Ann Surg. 257:17–26. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Capasso M, Franceschi M, Rodriguez-Castro KI, Crafa P, Cambiè G, Miraglia C, Barchi A, Nouvenne A, Leandro G, Meschi T, et al: Epidemiology and risk factors of pancreatic cancer. Acta Biomed. 89:141–146. 2018.PubMed/NCBI | |
|
Vilaverde F, Reis A, Rodrigues P, Carvalho A and Scigliano H: Adult pancreatoblastoma-case report and review of literature. J Radiol Case Rep. 31:28–38. 2016.PubMed/NCBI | |
|
Geurts JL: Inherited syndromes involving pancreatic neuroendocrine tumors. J Gastrointest Oncol. 11:559–566. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Q, Chen S, Zeng L, Chen Y, Lian G, Qian C, Li J, Xie R and Huang KH: New developments in the early diagnosis of pancreatic cancer. Expert Rev Gastroenterol Hepatol. 11:149–156. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Kolodecik T, Shugrue C, Ashat M and Thrower EC: Risk factors for pancreatic cancer: Underlying mechanisms and potential targets. Front Physiol. 16:4152014. | |
|
Haeberle L and Esposito I: Pathology of pancreatic cancer. Transl Gastroenterol Hepatol. 27:502019. View Article : Google Scholar : PubMed/NCBI | |
|
Pereira NP and Corrêa JR: Pancreatic cancer: Treatment approaches and trends. J Cancer Metastasis Treat. 4:302018. View Article : Google Scholar | |
|
Berardi R, Mandolesi A, Pellei C, Maccaroni E, Onofri A, Lucarelli A, Biagetti S, Alfonsi S, Caramanti M, Savini A, et al: Prognostic factors in pancreatic cancer: The role of perineural, vascular and lymphatic invasion and of Ca19-9. J Gastroint Dig Syst. 3:1342013. | |
|
Delpu Y, Hanoun N, Lulka H, Sicard F, Selves J, Buscail L, Torrisani J and Cordelier P: Genetic and epigenetic alterations in pancreatic carcinogenesis. Curr Genomics. 12:15–24. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Andrén-Sandberg A: Non-pancreatic cancer tumors in the pancreatic region. N Am J Med Sci. 3:55–62. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kaur S, Baine MJ, Jain M, Sasson AR and Batra SK: Early diagnosis of pancreatic cancer: Challenges and new developments. Biomark Med. 6:597–612. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Khan MA, Azim S, Zubair H, Bhardwaj A, Patel GK, Khushman M, Singh S and Singh AP: Molecular drivers of pancreatic cancer pathogenesis: Looking inward to move forward. Int J Mol Sci. 6:7792017. View Article : Google Scholar | |
|
Hruban RH and Fukushima N: Pancreatic adenocarcinoma: Update on the surgical pathology of carcinomas of ductal origin and PanINs. Mod Pathol. 20 (Suppl 1):S61–S70. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Fang Y, Yao Q, Chen Z, Xiang J, William FE, Gibbs RA and Chen C: Genetic and molecular alterations in pancreatic cancer: Implications for personalized medicine. Med Sci Monit. 31:916–926. 2013.PubMed/NCBI | |
|
Visani M, Acquaviva G, Leo AD, Sanza V, Merlo L, Maloberti T, Brandes AA, Franceschi E, Battista MD, Masetti M, et al: Molecular alterations in pancreatic tumors. World J Gastroenterol. 7:2710–2726. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Vernucci E, Abrego J, Gunda V, Shukla SK, Dasgupta A, Rai V, Chaika N, Buettner K, Illies A, Yu F, et al: Metabolic alterations in pancreatic cancer progression. Cancers (Basel). 18:22019. View Article : Google Scholar | |
|
Gil YR, Sánchez PJ, Velasco RM, García AG and Lobo VJ: Molecular alterations in pancreatic cancer: Transfer to the clinic. Int J Mol Sci. 19:20772021. | |
|
Pandol S, Edderkaoui M, Gukovsky I, Lugea A and Gukovskaya A: Desmoplasia of pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol. 7 (Suppl 11):S44–S47. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Merika EE, Syrigos KN and Saif MW: Desmoplasia in pancreatic cancer. Can we fight it? Gastroenterol Res Pract. 2012:7817652012.PubMed/NCBI | |
|
Annese T, Tamma R, Ruggieri S and Ribatti D: Angiogenesis in pancreatic cancer: Pre-clinical and clinical studies. Cancers (Basel). 18:3812019. View Article : Google Scholar | |
|
Li S, Xu HX, Wu CT, Wang WQ, Jin W, Gao HL, Li H, Zhang SR, Xu JZ, Qi ZH, et al: Angiogenesis in pancreatic cancer: Current research status and clinical implications. Angiogenesis. 22:15–36. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zeng S, Pöttler M, Lan B, Grützmann R, Pilarsky C and Yang H: Chemoresistance in pancreatic cancer. Int J Mol Sci. 11:45042019. View Article : Google Scholar | |
|
Grasso C, Jansen G and Giovannetti E: Drug resistance in pancreatic cancer: Impact of altered energy metabolism. Crit Rev Oncol Hematol. 114:139–152. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang S, Huang S and Sun YL: Epithelial-mesenchymal transition in pancreatic cancer: A review. Biomed Res Int. 2017:26461482017. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, Wu CC, LeBleu VS and Kalluri R: Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 527:525–530. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Safa AR: Epithelial-mesenchymal transition: A hallmark in pancreatic cancer stem cell migration, metastasis formation, and drug resistance. J Cancer Metastasis Treat. 6:362020. | |
|
Miura F, Takada T, Amano H, Yoshida M, Furui S and Takeshita K: Diagnosis of pancreatic cancer. HPB (Oxford). 8:337–342. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Song SW, Cheng JF, Liu N and Zhao TH: Diagnosis and treatment of pancreatic metastases in 22 patients: A retrospective study. World J Surg Oncol. 25:2992014. View Article : Google Scholar : PubMed/NCBI | |
|
Nalankilli K, Kannuthurai S and Moss A: A modern approach to ERCP: Maintaining efficacy while optimising safety. Dig Endosc. 28 (Suppl 1):S70–S76. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tryliskyy Y and Bryce GJ: Post-ERCP pancreatitis: Pathophysiology, early identification and risk stratification. Adv Clin Exp Med. 27:149–154. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Dietrich CF and Christian J: Modern ultrasound imaging of pancreatic tumors. Ultrasonography. 39:105–113. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Gañán IM, Ríos LF, de Toledo LS, Mombila ME and Mendoza LH: Estadificación mediante tomografía computarizada del carcinoma de páncreas. Radiologia. 60:10–23. 2018.(In English, Spanish). View Article : Google Scholar : PubMed/NCBI | |
|
Azzaz HE, Abdullah MS and Habib RM: Role of multidetector computed tomography in evaluation of resectability of pancreatic cancer. Egyptian J Radiol Nuclear Med. 52:1402021. View Article : Google Scholar | |
|
Deng L, Ke X, He Z, Yang D, Gong H, Zhang Y, Jing X, Yao J and Chen J: A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer. Int J Nanomedicine. 7:5053–5065. 2012.PubMed/NCBI | |
|
Le K, Wang J, Zhang T, Guo Y, Chang H, Wang S and Zhu B: Overexpression of mesothelin in pancreatic ductal adenocarcinoma (PDAC). Int J Med Sci. 17:422–427. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Jha P and Bijan B: PET/CT for pancreatic malignancy: Potential and pitfalls. J Nucl Med Technol. 43:92–97. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bhutani MS, Koduru P, Joshi V, Saxena P, Suzuki R, Irisawa A and Yamao K: The role of endoscopic ultrasound in pancreatic cancer screening. Endosc Ultrasound. 5:8–16. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Guijarro LG, Sanmartin-Salinas P, Pérez-Cuevas E, Toledo-Lobo MV, Monserrat J, Zoullas S, Sáez MA, Álvarez-Mon MA, Bujan J, Noguerales-Fraguas F, et al: Possible role of IRS-4 in the origin of multifocal hepatocellular carcinoma. Cancers (Basel). 23:25602021. View Article : Google Scholar | |
|
Majumder S, Chari ST and Ahlquist DA: Molecular detection of pancreatic neoplasia: Current status and future promise. World J Gastroenterol. 28:11387–11395. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kato K, Kamada H, Fujimori T, Aritomo Y, Ono M and Masaki T: Molecular biologic approach to the diagnosis of pancreatic carcinoma using specimens obtained by EUS-guided fine needle aspiration. Gastroenterol Res Pract. 2012:2435242012. View Article : Google Scholar : PubMed/NCBI | |
|
Hanada K, Minami T, Shimizu A, Fukuhara M, Yano S, Sasaki K, Koda M, Sugiyama K, Yonehara S and Yanagisawa A: Roles of ERCP in the early diagnosis of pancreatic cancer. Diagnostics (Basel). 7:302019. View Article : Google Scholar | |
|
Bispo M, Marques S, Rio-Tinto R, Fidalgo P and Devière J: The role of endoscopic ultrasound in pancreatic cancer staging in the Era of neoadjuvant therapy and personalised medicine. GE Port J Gastroenterol. 28:111–120. 2021.PubMed/NCBI | |
|
Sun B and Hu B: The role of intraductal ultrasonography in pancreatobiliary diseases. Endosc Ultrasound. 5:291–299. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Puri R, Manrai M, Thandassery RB and Alfadda AA: Endoscopic ultrasound in the diagnosis and management of carcinoma pancreas. World J Gastrointest Endosc. 25:67–76. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yamashita Y, Kato J, Ueda K, Nakamura Y, Kawaji Y, Abe H, Nuta J, Tamura T, Itonaga M, Yoshida T, et al: Contrast-enhanced endoscopic ultrasonography for pancreatic tumors. Biomed Res Int. 2015:4917822015. View Article : Google Scholar : PubMed/NCBI | |
|
Pentyala S, Whyard T, Pentyala S, Muller J, Pfail J, Parmar S, Helguero CG and Khan S: Prostate cancer markers: An update. Biomed Rep. 4:263–268. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Gonssaud B, Goussot V, Berriolo-Riedinger A, Saïtta-Aribau E, Coutant C, Cochet A, Fumoleau P and Riedinger JM: Clinical value of CA 15-3 for detection of distant metastases in newly diagnosed breast cancer. Ann Biol Clin (Paris). 1:421–429. 2017.PubMed/NCBI | |
|
Bottoni P and Scatena R: The role of CA 125 as tumor marker: Biochemical and clinical aspects. Adv Exp Med Biol. 867:229–244. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Coelho R, Silva M, Rodrigues-Pinto E, Cardoso H, Lopes S, Pereira P, Vilas-Boas F, Santos-Antunes J, Costa-Maia J and Macedo G: CA 19-9 as a marker of survival and a predictor of metastization in cholangiocarcinoma. GE Port J Gastroenterol. 24:114–121. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Poruk KE, Gay DZ, Brown K, Mulvihill JD, Boucher KM, Scaife CL, Firpo MA and Mulvihill SJ: The clinical utility of CA 19-9 in pancreatic adenocarcinoma: Diagnostic and prognostic updates. Curr Mol Med. 13:340–351. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Liu C, Deng S, Jin K, Gong Y, Cheng H, Fan Z, Qian Y, Huang Q, Ni Q, Luo G and Yu X: Lewis antigen-negative pancreatic cancer: An aggressive subgroup. Int J Oncol. 56:900–908. 2020.PubMed/NCBI | |
|
Salleh S, Thyagarajan A and Sahu RP: Exploiting the relevance of CA 19-9 in pancreatic cancer. J Cancer Metastasis Treat. 6:312020. | |
|
Amburn TL, Ginn M, Patel R, Pandalai PK, Kim J and Cavnar MJ: Clinical utility of symptoms and serum carbohydrate antigen (CA) 19-9 for detection of recurrence after curative intent resection of periampullary arcinoma. JACS. 231:E122–E1123. 2020. | |
|
Pereira SP, Oldfield L, Ney A, Hart PA, Keane MG, Pandol SJ, Li D, Greenhalf W, Jeon CY, Koay EJ, et al: Early detection of pancreatic cancer. Lancet Gastroenterol Hepatol. 5:698–710. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Agrawal S: Potential prognostic biomarkers in pancreatic juice of resectable pancreatic ductal adenocarcinoma. World J Clin Oncol. 10:255–260. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yip-Schneider MT, Soufi M, Carr RA, Flick KF, Wu H, Colgate CL and Schmidt CM: Performance of candidate urinary biomarkers for pancreatic cancer-correlation with pancreatic cyst malignant progression? Am J Surg. 219:492–495. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lim JH, Park JS and Yoon DS: Preoperative fecal elastase-1 is a useful prognostic marker following curative resection of pancreatic cancer. HPB (Oxford). 19:388–395. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Xu R, Xu Q, Huang G, Yin X, Zhu J, Peng Y and Song J: Combined analysis of the aberrant epigenetic alteration of pancreatic ductal adenocarcinoma. Biomed Res Int. 28:93798642019.PubMed/NCBI | |
|
Rückert F, Pilarsky C and Grützmann R: Serum tumor markers in pancreatic cancer-recent discoveries. Cancers (Basel). 2:1107–1124. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang J, Wang Y, Zhao T, Li Y, Tian L, Zhao J and Zhang J: Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer. World J Surg Oncol. 7:312020. View Article : Google Scholar | |
|
Kim H, Kang KN, Shin YS, Byun Y, Han Y, Kwon W, Kim CW and Jang JY: Biomarker panel for the diagnosis of pancreatic ductal adenocarcinoma. Cancers (Basel). 1:14432020. View Article : Google Scholar | |
|
Loosen SH, Neumann UP, Trautwein C, Roderburg C and Luedde T: Current and future biomarkers for pancreatic adenocarcinoma. Tumor Biol. 39:1010428317692232017. View Article : Google Scholar : PubMed/NCBI | |
|
Lee HS, Jang CY, Kim SA, Park SB, Jung DE, Kim BO, Kim HY, Chung MJ, Park JY, Bang S, et al: Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer. Sci Rep. 21:33832018. View Article : Google Scholar : PubMed/NCBI | |
|
Kim J, Bamlet WR, Oberg AL, Chaffee KG, Donahue G, Cao XJ, Chari S, Garcia BA, Petersen GM and Zaret KS: Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. Sci Transl Med. 12:eaah55832017. View Article : Google Scholar | |
|
Jenkinson C, Elliott VL, Evans A, Oldfield L, Jenkins RE, O'Brien DP, Apostolidou S, Gentry-Maharaj A, Fourkala EO, Jacobs IJ, et al: Decreased serum thrombospondin-1 levels in pancreatic cancer patients up to 24 months prior to clinical diagnosis: Association with diabetes mellitus. Clin Cancer Res. 22:1734–1743. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Radon TP, Massat NJ, Jones R, Alrawashdeh W, Dumartin L, Ennis D, Duffy SW, Kocher HM, Pereira SP, posthumous LG, et al: Identification of a three-biomarker panel in urine for early detection of pancreatic adenocarcinoma. Clin Cancer Res. 1:3512–3521. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Benassai G, Quarto G, Perrotta S, Furino E, Benassai GL, Amato B, Bianco T, Palma GD and Forestieri P: Long-term survival after curative resection for pancreatic ductal adenocarcinoma-surgical treatment. Int J Surg. 21 (Suppl 1):S1–S3. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Jeekel H: Prognostic factors following curative resection for pancreatic adenocarcinoma. Ann Surg. 240:3842004. View Article : Google Scholar : PubMed/NCBI | |
|
Brunner M, Wu Z, Krautz C, Pilarsky C, Grützmann R and Weber GF: Current clinical strategies of pancreatic cancer treatment and open molecular questions. Int J Mol Sci. 13:45432019. View Article : Google Scholar | |
|
Ho CK, Kleeff J, Friess H and Büchler MW: Complications of pancreatic surgery. HPB (Oxford). 7:99–108. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Andren-Sandberg A: Complications of pancreatic surgery. N Am J Med Sci. 3:531–535. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Liu M, Ji S, Xu W, Liu W, Qin Y, Hu Q, Sun Q, Zhang Z, Yu X and Xu X: Laparoscopic pancreaticoduodenectomy: Are the best times coming? World J Surg Oncol. 10:812019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu R, Cao Z, Qiu J and Zhang T: Minimally invasive pancreatic surgery: An upward spiral. Laparoscopic, Endoscopic and Robotic Surgery. 3:29–33. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Magge D, Zureikat A, Hogg M and Zeh HJ III: Minimally invasive approaches to pancreatic surgery. Surg Oncol Clin N Am. 25:273–286. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Liu R, Wakabayashi G, Palanivelu C, Tsung A, Yang K, Goh BK, Chong CC, Kang CM, Peng C, Kakiashvili E, et al: International consensus statement on robotic pancreatic surgery. Hepatobiliary Surg Nutr. 8:345–360. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Rashid OM, Mullinax JE, Pimiento JM, Meredith KL and Malafa MP: Robotic whipple procedure for pancreatic cancer: The moffitt cancer center pathway. Cancer Control. 22:340–351. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Rehders A, Stoecklein NH, Güray A, Riediger R, Alexander A and Knoefel WT: Vascular invasion in pancreatic cancer: Tumor biology or tumor topography? Surgery. 152 (Suppl 1):S143–S151. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zaky AM, Wolfgang CL, Weiss MJ, Javed AA, Fishman EK and Zaheer A: Tumor-vessel relationships in pancreatic ductal adenocarcinoma at multidetector CT: Different classification systems and their influence on treatment planning. Radiographics. 37:93–112. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Dua MM, Tran TB, Klausner J, Hwa KJ, Poultsides GA, Norton JA and Visser BC: Pancreatectomy with vein reconstruction: Technique matters. HPB (Oxford). 17:824–831. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Delpero JR and Sauvanet A: Vascular resection for pancreatic cancer: 2019 French recommendations based on a literature review from 2008 to 6-2019. Front Oncol. 4:402020. View Article : Google Scholar : PubMed/NCBI | |
|
Sgroi MD, Narayan RR, Lane JS, Demirjian A, Kabutey NK, Fujitani RM and Imagawa DK: Vascular reconstruction plays an important role in the treatment of pancreatic adenocarcinoma. J Vasc Surg. 61:475–480. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Rebelo A, Michalski C, Ukkat J and Kleeff J: Pancreatic cancer surgery with vascular resection: Current concepts and perspectives. J Pancreatol. 2:1–5. 2019. View Article : Google Scholar | |
|
Perinel J and Adham M: Palliative therapy in pancreatic cancer-palliative surgery. Transl Gastroenterol Hepatol. 7:282019. View Article : Google Scholar : PubMed/NCBI | |
|
Pencovich N, Orbach L, Lessing Y, Elazar A, Barnes S, Berman P, Blachar A, Nachmany I and Sagie B: Palliative bypass surgery for patients with advanced pancreatic adenocarcinoma: Experience from a tertiary center. World J Surg Oncol. 1:632020. View Article : Google Scholar : PubMed/NCBI | |
|
Assfalg V, Hüser N, Michalski C, Gillen S, Kleeff J and Friess H: Palliative interventional and surgical therapy for unresectable pancreatic cancer. Cancers (Basel). 14:652–661. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Pezzilli R: Neuropathic pain in pancreatic cancer: An update of the last five years. Gastroenterol Insights. 12:302–309. 2021. View Article : Google Scholar | |
|
Zhong W, Yu Z, Zeng JX, Lin Y, Yu T, Min XH, Yuan YH and Chen QK: Celiac plexus block for treatment of pain associated with pancreatic cancer: A meta-analysis. Pain Pract. 14:43–51. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Springfeld C, Jäger D, Büchler MW, Strobel O, Hackert T, Palmer DH and Neoptolemos JP: Chemotherapy for pancreatic cancer. Presse Med. 48:e159–e174. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hajatdoost L, Sedaghat K, Walker EJ, Thomas J and Kosari S: Chemotherapy in pancreatic cancer: A systematic review. Medicina (Kaunas). 11:482018. View Article : Google Scholar | |
|
Marco MD, Cicilia RD, Macchini M, Nobili E, Vecchiarelli S, Brandi G and Biasco G: Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review). Oncol Rep. 23:1183–1192. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Martín AM, Hidalgo M, Alvarez R, Arrazubi V, Martínez-Galán J, Salgado M, Macarulla T and Carrato A: From first line to sequential treatment in the management of metastatic pancreatic cancer. J Cancer. 30:1978–1988. 2018. View Article : Google Scholar | |
|
Conroy T, Hammel P, Hebbar M, Abdelghani MB, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, et al: FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 20:2395–2406. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Azam F, Latif MF, Farooq A, Tirmazy SH, AlShahrani S, Bashir S and Bukhari N: Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals. Case Rep Oncol. 25:728–736. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Lee J, Lee JC, Gromski MA, Kim HW, Kim J, Kim J and Hwang JH: Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience. Medicine (Baltimore). 97:e135922018. View Article : Google Scholar : PubMed/NCBI | |
|
Yoo C, Kang J, Kim KP, Lee JL, Ryoo BY, Chang HM, Lee SS, Park DH, Song TJ, Seo DW, et al: Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: Improved efficacy compared with gemcitabine-based regimen. Oncotarget. 11:46337–46347. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tahara J, Shimizu K, Otsuka N, Akao J, Takayama Y and Tokushige K: Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 82:245–250. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ma P and Mumper RJ: Paclitaxel nano-delivery systems: A comprehensive review. J Nanomed Nanotechnol. 18:10001642013.PubMed/NCBI | |
|
Chatterjee M, Ben-Josef E, Robb R, Vedaie M, Seum S, Thirumoorthy K, Palanichamy K, Harbrecht M, Chakravarti A and Williams TM: Caveolae-mediated endocytosis is critical for albumin cellular uptake and response to albumin-bound chemotherapy. Cancer Res. 1:5925–5937. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yardley DA: Nab-paclitaxel mechanisms of action and delivery. J Control Release. 28:365–372. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kang J, Hwang I, Yoo C, Kim KP, Jeong JH, Chang HM, Lee SS, Park DH, Song TJ, Seo DW, et al: Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: Retrospective analysis. Invest New Drugs. 36:732–741. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kim G: Nab-paclitaxel for the treatment of pancreatic cancer. Cancer Manag Res. 16:85–96. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wolfe AR, Prabhakar D, Yildiz VO, Cloyd JM, Dillhoff M, Abushahin L, Diaz DA, Miller ED, Chen W, Frankel WL, et al: Neoadjuvant-modified FOLFIRINOX vs. nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection. Cancer Med. 9:4711–4723. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Sarabi M, Mais L, Oussaid N, Desseigne F, Guibert P and Fouchardiere CD: Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma. Oncol Lett. 13:4917–4924. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kordes M, Yu J, Malgerud O, Liljefors MG and Löhr JM: Survival benefits of chemotherapy for patients with advanced pancreatic cancer in a clinical real-world cohort. Cancers (Basel). 7:13262019. View Article : Google Scholar | |
|
Oba A, Ho F, Bao QR, Al-Musawi MH, Schulick RD and Chiaro MD: Neoadjuvant treatment in pancreatic cancer. Front Oncol. 28:2452020. View Article : Google Scholar : PubMed/NCBI | |
|
Versteijne E, Vogel JA, Besselink MG, Busch OR, Wilmink JW, Daams JG, van Eijck CHJ, Koerkamp BG, Rasch CR, van Tienhoven G, et al: Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 105:946–958. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Seufferlein T and Ettrich TJ: Treatment of pancreatic cancer-neoadjuvant treatment in resectable pancreatic cancer (PDAC). Transl Gastroenterol Hepatol. 27:212019. View Article : Google Scholar : PubMed/NCBI | |
|
Müller PC, Frey MC, Ruzza CM, Nickel F, Jost C, Gwerder C, Hackert T, Z'graggen K and Kessler U: Neoadjuvant chemotherapy in pancreatic cancer: An appraisal of the current high-level evidence. Pharmacology. 106:143–153. 2021.PubMed/NCBI | |
|
Hall WA and Karyn A: Goodman: Radiation therapy for pancreatic adenocarcinoma, a treatment option that must be considered in the management of a devastating malignancy. Radiat Oncol. 26:1142019. View Article : Google Scholar : PubMed/NCBI | |
|
Tchelebi LT, Zaorsky NG, Rosenberg JC, Sharma NK, Tuanquin LC, Mackley HB and Ellis RJ: Reducing the toxicity of radiotherapy for pancreatic cancer with magnetic resonance-guided radiotherapy. Toxicol Sci. 1:19–23. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Buwenge M, Macchia G, Arcelli A, Frakulli R, Fuccio L, Guerri S, Grassi E, Cammelli S, Cellini F and Morganti AG: Stereotactic radiotherapy of pancreatic cancer: A systematic review on pain relief. J Pain Res. 4:2169–2178. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Palta M, Godfrey D, Goodman KA, Hoffe S, Dawson LA, Dessert D, Hall WA, Herman JM, Khorana AA, Merchant N, et al: Radiation therapy for pancreatic cancer: Executive summary of an ASTRO clinical practice guideline. Pract Radiat Oncol. 9:322–332. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Shah AP, Strauss JB and Abrams RA: Review and commentary on the role of radiation therapy in the adjuvant management of pancreatic cancer. Am J Clin Oncol. 33:101–106. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang W, Haque W, Verma V, Butler EB and Teh BS: Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma. Acta Oncol. 58:1259–1266. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Glicksman RM, Chung H, Myrehaug S, Erler D, Korol R, Karotki A, Taggar A and Ung YC: Stereotactic radiotherapy for pancreatic cancer: A single-institution experience. Cureus. 23:e106182020.PubMed/NCBI | |
|
Gou Q, Dong C, Xu H, Khan B, Jin J, Liu Q, Shi J and Hou Y: PD-L1 degradation pathway and immunotherapy for cancer. Cell Death Dis. 6:9552020. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang T, Shi T, Zhang H, Hu J, Song Y, Wei J, Ren S and Zhou C: Tumor neoantigens: From basic research to clinical applications. J Hematol Oncol. 6:932019. View Article : Google Scholar | |
|
Das M, Zhou X, Liu Y, Das A, Vincent BG, Li J, Liu R and Huang L: Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth. Transl Oncol. 13:1008562020. View Article : Google Scholar : PubMed/NCBI | |
|
Chi J, Patel R, Rehman H, Goyal S and Saif MW: Recent advances in immunotherapy for pancreatic cancer. J Cancer Metastasis Treat. 6:432020. | |
|
Chen H, Yang G, Xiao J, Zheng L, You L and Zhang T: Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC). Cancer Lett. 10:12–19. 2020. View Article : Google Scholar | |
|
Looi CK, Chung FFL, Leong CO, Wong SF, Rosli R and Mai CW: Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. J Exp Clin Cancer Res. 15:1622019. View Article : Google Scholar : PubMed/NCBI | |
|
Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I and Rosenberg SA: Phase 2 trial of single agent ipilimumab (Anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 33:828–833. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL and Anders RA: Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 1:5064–5074. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Amin S, Baine M, Meza J, Alam M and Lin C: The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor. Clin Transl Radiat Oncol. 7:34–40. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Brouwer TP, Vahrmeijer AL and de Miranda NF: Immunotherapy for pancreatic cancer: Chasing the light at the end of the tunnel. Cell Oncol (Dordr). 44:261–278. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Krishnamoorthy M, Lenehan JG, Burton JP and Vareki SM: Immunomodulation in pancreatic cancer. Cancers (Basel). 12:33402020. View Article : Google Scholar : PubMed/NCBI | |
|
Sideras K, Braat H, Kwekkeboom J, van Eijck CH, Peppelenbosch MP, Sleijfer S and Bruno M: Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. Cancer Treat Rev. 40:513–522. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Amedei A, Niccolai E and Prisco D: Pancreatic cancer: Role of the immune system in cancer progression and vaccine-based immunotherapy. Hum Vaccin Immunother. 10:3354–3368. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Luo W, Yang G, Luo W, Cao Z, Liu Y, Qiu J, Chen G, You L, Zhao F, Zheng L and Zhang T: Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: Vaccine therapy is more than just a theory. Cancer Cell Int. 4:662020. View Article : Google Scholar : PubMed/NCBI | |
|
Akce M, Zaidi MY, Waller EK, El-Rayes BF and Lesinski GB: The potential of CAR T cell therapy in pancreatic cancer. Front Immunol. 25:21662018. View Article : Google Scholar : PubMed/NCBI | |
|
Penack O and Koenecke C: Complications after CD19+ CAR T-cell therapy. Cancers (Basel). 19:34452020. View Article : Google Scholar | |
|
Golan T, Hammel P, Reni M, Cutsem EV, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, et al: Maintenance olaparib for germline brca-mutated metastatic pancreatic cancer. N Engl J Med. 25:317–327. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Picozzi V, Alseidi A, Winter J, Pishvaian M, Mody K, Glaspy J, Larson T, Matrana M, Carney M, Porter S, et al: Gemcitabine/nab-paclitaxel with pamrevlumab: A novel drug combination and trial design for the treatment of locally advanced pancreatic cancer. ESMO Open. 5:e0006682020. View Article : Google Scholar : PubMed/NCBI | |
|
Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R Jr, Topaloglu U, et al: Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: A single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol. 18:770–778. 2017. View Article : Google Scholar : PubMed/NCBI |
